glenzocimab

Phase 2Monoclonal antibody

AActicor Biotech

glenzocimab is one of 97 small molecule programs targeting Stroke. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

StrokeActive, not recruiting

Brain InfarctionActive, not recruiting

Stroke, AcuteCompleted

Acute Respiratory Distress SyndromeActive, not recruiting

Ischemic StrokeActive, not recruiting

StrokePhase 2/Phase 3

Active, not recruiting

Brain InfarctionPhase 2/Phase 3

Active, not recruiting

Stroke, AcutePreclinical

Completed

Acute Respiratory Distress SyndromePhase 2

Active, not recruiting

Ischemic StrokePhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

461 competitors in Stroke

#DrugCompanyPhaseTrials

glenzocimab

AActicor Biotech

Phase 2

1 2

Zometa

Pfizer

Preclinical

1 3

Folvite

Eli Lilly

Preclinical

1 4

Savella

AbbVie

Preclinical

1 5

Proamatine

Repatha

Pradaxa

3 8

Botox

RRevance Therapeutics, Inc.

Preclinical

2 9

Periactin

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 10

Alka-Seltzer

AAbbott

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Phase 2/3Not yet recruiting

Stroke

NCT06437431

Clinical

Trials by Indication[1]

Stroke1 trial

Glenzocimab in Anterior Stroke With Large Ischemic Core Eligible for Endovascular Therapy

Not yet recruiting·FFondation Ophtalmologique Adolphe de Rothschild·Phase 2/3·NCT06437431·304 enrolled

Ischemic stroke1 trial

ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo

Completed·AActicor Biotech·Phase 2/3·NCT05070260·438 enrolled

Acute Respiratory Distress Syndrome1 trial

Glenzocimab in SARS-Cov-2 Acute Respiratory DistrEss syNdrome Related to COVID-19

Completed·AActicor Biotech·Phase 2·NCT04659109·60 enrolled

Stroke, Acute1 trial

Glenzocimab for REperfusion in the Setting of Endovascular Therapy for Brain infarctioN: GREEN Study

Completed·AAssistance Publique - Hôpitaux de Paris·Preclinical·NCT05559398·108 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for glenzocimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — glenzocimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for glenzocimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Acticor Biotech company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: AActicor Biotech

glenzocimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Stroke1 trial

Ischemic stroke1 trial

Acute Respiratory Distress Syndrome1 trial

Stroke, Acute1 trial

References

Drug Info

Quick Facts

Related News